July 23, 2026

FDA Approves Zidesamtinib for ROS1 Lung Cancer

Phase 1/2 ARROS-1 data showed a 44% objective response rate, with most responses ongoing at 6 months.

Conexiant

July 23, 2026

Conservative Management May Be Safe for Small Mediastinal Lesions

Most anterior mediastinal lesions smaller than 3 cm remained stable during annual computed tomography surveillance, supporting a conservative management strategy for selected patients in lung cancer screening.

Conexiant

July 17, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Conexiant

July 14, 2026

Oversight May Be Critical in Patient Acceptance of AI in Radiology

A UK survey found that patients supported AI as a clinical tool but wanted physicians to remain responsible for medical decisions.

Conexiant

July 13, 2026

Does Pediatric Readiness Reduce ED Imaging?

Hospitals with stronger pediatric emergency capability used less imaging overall, but differences by insurance status and race and ethnicity remained.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 02, 2026

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

Conexiant

June 01, 2026

Can Proteomics Refine Lung Screening?

Proteomic biomarkers improve short-term lung cancer risk assessment.

Conexiant

May 29, 2026

AI Shows Promise for Intraoperative Lung Adenocarcinoma Assessment

A smartphone image–centered deep learning model showed promise for intraoperative diagnosis and grading of clinical stage IA lung adenocarcinoma, but grade-specific limitations and lack of outcomes data mean the tool remains investigational.

Conexiant

May 20, 2026

AI Drafts Cut Radiograph Reporting Time

Prospective cohort study found faster documentation, with no statistically significant difference in peer-reviewed report quality

Conexiant